December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP:BAYRY)

10.52 -0.02 (-0.24%)
Streaming Delayed Price Updated: 10:34 AM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Aktienges ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
From Bayer
Via Business Wire
News headline image
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
From Bayer
Via Business Wire
News headline image
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
From Bayer
Via Business Wire
Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt ↗
Via Stocktwits
News headline image
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
From Bayer
Via Business Wire
News headline image
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
From Bayer
Via Business Wire
News headline image
FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising ↗
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for advanced lung cancer. 
Via Benzinga
News headline image
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target ↗
 
Via Benzinga
News headline image
Daré Bioscience (DARE) Q3 2025 Earnings Transcript ↗
Daré Bioscience (DARE) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks ↗
Bayer's Q3 earnings rose on strong Crop Science and Pharma sales, with CEO Bill Anderson confident in meeting the company's upgraded 2025 guidance. 
Via Benzinga
News headline image
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
From Bayer
Via Business Wire
News headline image
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
From Bayer
Via Business Wire
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
 
Via Benzinga
News headline image
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
From Bayer
Via Business Wire
News headline image
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients. 
Via Benzinga
News headline image
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
From Bayer
Via Business Wire
News headline image
One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”
From Bayer
Via Business Wire
News headline image
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
From Bayer
Via Business Wire
News headline image
Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
From Bayer
Via Business Wire
News headline image
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
From Bayer
Via Business Wire
News headline image
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
From Bayer
Via Business Wire
News headline image
10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign
From Bayer
Via Business Wire
News headline image
Agri-Science Giant Corteva Eyes Breakup To Shield Seed Unit From Future Risks: Report ↗
Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid falling crop prices and rising costs. 
Via Benzinga
News headline image
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
From Bayer
Via Business Wire
News headline image
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
From Bayer
Via Business Wire
News headline image
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
From Bayer
Via Business Wire
News headline image
Retail Turns Bearish On Bayer After $1.3B Kumquat Cancer Drug Deal ↗
Bayer and Kumquat Biosciences have signed an exclusive global license and collaboration to develop a KRAS G12D inhibitor, with potential milestone payments of up to $1.3 billion 
Via Stocktwits
News headline image
OTC Markets Group Announces Quarterly Index Performance and Rebalancing
From OTC Markets
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.